CompletedPhase 3

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

United States175 participantsStarted 2023-06-20

Plain-language summary

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ≥ 15 mm in one or more myocardial segments OR
✓. ≥ 13 mm in one or more wall segments and a known disease-causing gene mutation or positive family history of HCM

Exclusion criteria

✕. Moderate-severe valvular aortic stenosis or fixed subaortic obstruction
✕. Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator judgment)

What they're measuring

Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET)

Timeframe: Baseline to Week 24

Trial details

NCT IDNCT05767346

SponsorCytokinetics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-28

View on ClinicalTrials.gov More Obstructive Hypertrophic Cardiomyopathy (oHCM) trials